<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01632566</url>
  </required_header>
  <id_info>
    <org_study_id>14284</org_study_id>
    <secondary_id>I5W-EW-LBCB</secondary_id>
    <nct_id>NCT01632566</nct_id>
  </id_info>
  <brief_title>A Multiple-dose Study of LY3031207 in Healthy Participants</brief_title>
  <official_title>A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3031207 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to look at safety, how well the study drug is tolerated, how
      much of the study drug gets into the blood stream, and how long it takes the body to get rid
      of it when given to healthy Japanese and non-Japanese participants as multiple doses. In
      addition, effects of 28-day oral dosing of LY3131207 on the amount of a cholesterol-lowering
      drug (simvastatin) that gets into the blood stream and how long the body takes to get rid of
      it will be determined. The effects of LY3131207 after single and 28-day dosing on blood
      pressure will also be studied. Information about any side effects that may occur will be
      collected.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in some
    participants.
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with one or more drug related adverse events (AEs) or any serious AEs</measure>
    <time_frame>Baseline to study completion (estimated at 16 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (Cmax) of LY3031207</measure>
    <time_frame>Predose up to 48 hours post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration curve (AUC) of LY3031207</measure>
    <time_frame>Predose up to 48 hours post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time of maximum concentration (Tmax) of LY3031207</measure>
    <time_frame>Predose up to 48 hours post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (Cmax) of simvastatin</measure>
    <time_frame>Predose up to 48 hours post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration curve (AUC) of simvastatin</measure>
    <time_frame>Predose up to 48 hours post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time of maximum concentration (Tmax) of simvastatin</measure>
    <time_frame>Predose up to 48 hours post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline of urinary prostacyclin I (PGI) metabolite excretion</measure>
    <time_frame>Predose up to 12 hours prior to last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline of urinary prostaglandin E (PGE) metabolite excretion</measure>
    <time_frame>Predose up to time of last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline of urinary thromboxane A (TXA) metabolite excretion</measure>
    <time_frame>Predose up to 12 hours prior to last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily oral administration of placebo for 28 days. Dose will match corresponding LY3031207 dosage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3031207</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral administration of 25 milligrams up to 450 milligrams of LY3031207 for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily oral administration of 400 milligrams celecoxib for 28 days. Positive control for LY3031207.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3031207 + Simvastatin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Daily oral administration of 75 milligram or 225 milligram of LY3031207 for 28 days. Single oral 10 milligram dose of simvastatin administered open label before and after 28-day dosing of LY3031207.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3031207</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3031207</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Celecoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3031207 + Simvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy individuals based on the history and physical examinations as
             determined by the investigator, including first generation Japanese

          -  Body mass index between 17.0 and 32.0 kilograms per square meter (kg/m^2), inclusive

        Exclusion Criteria:

          -  Have known allergies to LY3031207 or any components of the formulation, simvastatin or
             related compounds (other 3-Hydroxy-3-Methyl-Glutaryl-CoA [HMG CoA] reductase
             inhibitors), celecoxib, or sulfonamides. Participants with known aspirin allergy or
             allergic reaction to nonsteroidal anti-inflammatory drugs (NSAIDs) should also be
             excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri, 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2012</study_first_submitted>
  <study_first_submitted_qc>July 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2012</study_first_posted>
  <last_update_submitted>April 30, 2013</last_update_submitted>
  <last_update_submitted_qc>April 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

